Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Active:	Yes
Cancer Type:	Lung Cancer	NCT ID:	NCT06881784
Trial Phases:	Phase III	Protocol IDs:	RMC-6236-301 (primary) NCI-2025-02939
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Revolution Medicines, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT06881784

Summary

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON)
inhibitor compared to docetaxel.

Objectives

This is a global, randomized, open-label, Phase 3 study designed to evaluate whether
treatment with daraxonrasib will improve progression free survival (PFS) or overall
survival (OS) compared to docetaxel chemotherapy in patients with NSCLC who were
previously treated. Patients will be randomized in a 1:1 ratio to receive daraxonrasib or
docetaxel chemotherapy.

Treatment Sites in Georgia

University Cancer and Blood Center, LLC - Athens Medical Oncology
3320 Old Jefferson Road
Building 800
Athens, GA 30607
www.universitycancer.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.